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The GARY Registry*Jean-Michel Paradis, MD, Josep Rodés-Cabau, MDSEE PAGE 2173A lthough randomized trials have been pivotalin establishing transcatheter aortic valvereplacement (TAVR) as a treatment strategy
for patients with severe aortic stenosis and high
surgical risk (1–3), several registries have also
featured prominently in consolidating this technol-
ogy. Registry-based data have inherent limitations,
including data accuracy and completeness, potential
selection bias due to nonrandomized allocation of in-
terventions and devices, frequent lack of data moni-
toring and endpoint adjudication, and the presence
of unmeasured confounders. Nevertheless, registries
allow the comparison of large “real-world” patient
populations, permit post-market approval device sur-
veillance, minimize bias in reporting individual cen-
ter and operator outcomes, and could eventually
lead to an international network of registries for
global device surveillance.
The TAVR ﬁeld comprises several important
industry-driven registries, although this type of reg-
istry generates data with an inherent selection bias.
Alternatively, registries with mandatory data collec-
tion on a national scale utilizing an all-comers
approach would ultimately provide the most reliable
data on both patient characteristics and real-world
results. Such was the case with both the FRANCE 2
(French Aortic National CoreValve and Edwards) and
TVT (Transcatheter Valve Therapies) registries (4,5),*Editorials published in the Journal of the American College of Cardiology
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ﬁlling the requirements of the French Ministry of
Health and the Centers for Medicare & Medicaid Ser-
vices, respectively.
The German Aortic Valve Registry (GARY), founded
in July 2010, was assembled as a complete survey for
all invasive therapies in patients with signiﬁcant
aortic valve diseases (6). Surgical aortic valve re-
placement (SAVR) and new treatment options such as
TAVR are being monitored. Importantly, data acqui-
sition is based on 3 sources: 1) the mandatory German
database for external performance measurement;
2) a speciﬁcally-developed registry dataset; and 3) a
follow-up data sheet, which was ﬁlled in by telephone
interview (6). Apart from the 30-day clinical status, all
other follow-up evaluations (1, 3, and 5 years) are
accomplished independently by the Institute for
Quality and Patient Safety.In this issue of the Journal, Walther et al. (7) report
the acute results and periprocedural complications of
15,964 patients included in GARY who underwent
TAVR in 88 German centers between 2011 and 2013
(7). Notably, GARY not only provides solid evidence
on TAVR results from an all-comers and real-world
perspective, it also represents the largest published
TAVR registry to date. Similar to prior registries, the
mean age of patients was >80 years; however, the
median Society of Thoracic Surgeons (STS) risk score
was 5%, much lower than the risk proﬁle reported in
most previous TAVR studies including randomized
trials (1–3,8) as well as the all-comers FRANCE 2 and
TVT registries (4,5). Furthermore, patient risk pro-
gressively decreased over time, highlighting the
shift in Germany toward treating lower surgical-risk
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exempliﬁes the likely worldwide shift of TAVR in
the ensuing years. However, further conﬁrmation of
TAVR’s noninferiority compared with SAVR in lower-
risk populations is mandatory, and there are ran-
domized trials in the recruitment stage that will
certainly help answer this unresolved question.
Meanwhile, the recently-reported results from a
prospective randomized trial showed lack of mortal-
ity and stroke differences at 1-year follow-up between
TAVR and SAVR in 280 low-risk patients (mean STS:
3%) (9). These promising results, in addition to 5-year
data from the PARTNER (Placement of Aortic Trans-
catheter Valves) trial showing absence of structural
failures of the transcatheter and surgical valves (10),
sets the scene for the likely expansion of TAVR to-
ward treating both lower-risk and younger patients.
The work of Walther et al. (7) focused on in-
hospital outcomes post-TAVR. Unfortunately, the
authors failed to report the (more standard) 30-day
data, making it somewhat difﬁcult to compare with
most prior TAVR studies. Most patients were treated
transfemorally (71%), with the transapical approach
used in 27% of patients. About one-half of the
patients received a balloon-expandable valve and
one-half received a self-expanding valve system. The
in-hospital mortality rate of 5.2% was close to the pre-
operative risk determined by the STS score (median:
5%) or the German Aortic Valve score (median: 5.6%)
but was much lower than the logistic EuroSCORE
median (18.3%). GARY adds to the widely demon-
strated outcome that the logistic EuroSCORE signiﬁ-
cantly overestimates the procedural risk of TAVR
candidates. The acute mortality reported in GARY
compares favorably with prior all-comer registries
including higher-risk patients like FRANCE-2 (mean
STS: 14%; 30-day mortality: 9.7%) and TVT (median
STS: 7.1%; 30-day mortality: 7.0%) (5,6). Up to 20
baseline and periprocedural variables (mostly proce-
dural complications) were associated with in-hospital
mortality. Hence, these data essentially conﬁrm what
has already been reported in numerous prior TAVR
studies (8). Interestingly, and unlike other registries
(4,5), the transapical approach was not an indepen-
dent predictor of mortality in GARY.
The in-hospital stroke rate (1.5%) was lower
than those reported in randomized trials including
neurological assessment both before and following
TAVR (between 4.9% and 6.7%) (1–3). This might
be explained by GARY’s lower-risk population,
the learning curve effect, or technology advances
reducing valve embolization rates, need for a second
valve, and so on. Additionally, it would have been
interesting to know the rate of embolic protectiondevice use (if any) during TAVR. This lower stroke
rate aligns with other contemporary reports of peri-
procedural cerebrovascular event rates <3% (5,9).
Moderate or severe aortic regurgitation (AR) has
been identiﬁed as one of TAVR’s most important
drawbacks (1–3,8). Importantly, moderate or severe
AR was reported in <6% of GARY cases, almost one-
half the rate reported in prior studies. Although this
ﬁnding should be interpreted with caution due to the
high variability in AR evaluation in the absence of a
central core laboratory, this lower rate of AR reﬂects
the current trend in the TAVR ﬁeld, which is likely
related to better transcatheter valve sizing and posi-
tioning, as well as the use of newer-generation de-
vices with enhanced antiparavalvular leak properties
(8), although the rate of use of such devices was not
provided.
To further evaluate procedural safety, Walther
et al. (7) created 2 novel composite endpoints for
reporting periprocedural complications: 1) severe
vital complications (SVC) including death on the
day of intervention, conversion to sternotomy, acute
percutaneous coronary intervention, low cardiac
output requiring treatment, aortic dissection, or an-
nular rupture; and 2) technical complications (TCO)
including the repositioning or retrieval of the valve
prosthesis, valve-in-valve procedure, valve emboli-
zation, or paravalvular leak closure. SVC and TCO
occurred in 5.0% and 4.7% of patients, respectively,
and both categories of complications decreased
signiﬁcantly over time. Again, this favorable ten-
dency could be explained by technical progress
(retrievable valves, antiparavalvular leak properties),
constant learning, improved screening, and treating
progressively lower-risk patients. Of note, the inci-
dence of complications requiring urgent sternotomy
was 1.3%, with >50% of patients surviving such
complications. This underscores the importance of
performing these procedures in centers with surgical
facilities.
Although these novel combined endpoints (SVC
and TCO) help provide a rapid overview of procedural
safety, they have several drawbacks. First, they are
vastly different from the consensus endpoint deﬁni-
tions established by the Valve Academic Research
Consortium (11). Although original, this new para-
digm of outcomes assessment may render compre-
hensive evaluation of GARY rather complex and make
the comparison of interstudy results extremely chal-
lenging. Second, identifying the predictors of life-
threatening complications is key for implementing
appropriate preventive measures. The authors iden-
tiﬁed the following independent predictors of SVC:
female sex, New York Heart Association functional
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operative inotropic medication, peripheral vascular
disease, higher degree of valve calciﬁcation, and
grade IV aortic stenosis. For TCO, the independent
predictors were male sex, ejection fraction #30%,
neurological dysfunction, cardiac decompensation,
intravenous inotrope therapy, and year of the proce-
dure. However, the complications included in each
combined endpoint are very diverse, raising ques-
tions as to the validity and clinical application of
these data. For example, it is well known that the
predictors of mechanical complications such as cor-
onary obstruction or annulus rupture are inherently
different from those of low cardiac output syndrome.
Not surprisingly, the authors failed to ﬁnd any pre-
dictor for conversion to sternotomy. Again, because
this complication can be related to a myriad of
causes (ventricular perforation, coronary obstruction,
annulus rupture, and so on), each one of them
should probably be analyzed separately to ascertain
clinically-meaningful predictors. In our opinion,
GARY represents a unique opportunity to analyze
the factors associated with each individual life-
threatening or technical complication of TAVR. This
would generate more clinically-meaningful data that
could be applied when evaluating TAVR candidates as
well as for pre-operative planning.Compared with other industrialized nations, TAVR
has expanded most rapidly in Germany. With the data
from GARY, it is reassuring that TAVR’s growth ap-
pears safe. The heart team approach, involving the
collaborative work of cardiologists, cardiac surgeons,
anesthesiologists, and imaging specialists, remains
fundamental for optimizing clinical outcomes. GARY
highlights the ability to monitor the evolution of risk
proﬁle, procedural success, and acute complications
in a vast number of patients. This may allow us to
detect, among others, changes in patients’ charac-
teristics and risk proﬁle as well as major differences
between valve types, approaches, or other speciﬁcs
relating to individual treatment centers that could
permit corrective actions on the basis of unantici-
pated negative outcomes and treatment gaps. None-
theless, in the burgeoning TAVR arena, standardizing
clinical research is essential. We strongly encourage
international societies to utilize the accepted Valve
Academic Research Consortium deﬁnitions for
improving comparability and interpretability of the
ever-expanding TAVR data bank.
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